Abstract:Introduction Previous studies suggested that estrogen receptor alpha (ERα) plays an important role in the chemoresistance of breast cancers. However, large random trials failed to demonstrate any benefit of the concurrent estrogen antagonist tamoxifen on the chemotherapy efficacy. Thus, in the present study, the importance of the role of ERα in the chemoresistance of breast cancer cells was investigated. Methods The ERα-transfected Bcap37 cells and natural ERα-positive T47D breast cancer cells were treated using chemotherapeutic agents with or without 17-beta estradiol (E2) pretreatment. Their viabilities were assessed using 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide assays. The dead cell rates were determined using propidium iodide dye exclusion tests, and the expression levels of Bcl-2 and Bax were detected through Western blot analysis. The effects of E2 on the growth of breast cancer cells were also determined via cell growth curve and cell cycle analysis. Results ERα activation by E2 increased the sensitivity of natural ERα-positive T47D breast cancer cells to chemotherapeutic agents. However, the increase in ERα expression in ERα-negative Bcap37 breast cancer cells also significantly increased their resistance. These phenomena cannot be explained by asserting that ERα mediated the chemoresistance of breast cancer cells by regulating the expression of Bcl-2 and Bax. Our findings show that ERα activation upregulated the expression of Bcl-2 in natural ERα-positive T47D breast cancer cells, whereas ERα activation by E2 downregulated and upregulated the Bcl-2 and Bax expression levels, respectively, in ERα-transfected Bcap37 cells. This phenomenon was due to the influence of ERα on the growth of breast cancer cells. Specifically, ERα activation enhanced the growth of natural ERα-positive breast cancer cells and thus increased their sensitivity to chemotherapeutic agents. However, ERα activation also inhibited the growth of ERα-transfected Bcap37 cells and increased the resistance of cancer cells to chemotherapeutic agents. Chemoresistance of ERα-transfected Bcap37 cells was only due to the specific growth inhibition by E2, which is not applicable to common ERα-positive breast cancer cells. Conclusions Although ERα was associated with chemoresistance of breast cancers, ERα itself did not mediate this resistance process.

Predictive Features of Ligand‐specific Signaling Through the Estrogen Receptor

Selective Ligands of Estrogen Receptor Β Discovered Using Pharmacophore Mapping and Structure-Based Virtual Screening.

The role of estrogen receptor alpha in mediating chemoresistance in breast cancer cells

In Silico Prediction of Estrogen Receptor Subtype Binding Affinity and Selectivity Using 3D-QSAR and Molecular Docking

In Silico Prediction of Estrogen Receptor Subtype Binding Affinity and Selectivity Using Statistical Methods and Molecular Docking with 2-Arylnaphthalenes and 2-Arylquinolines

Analysis of ligand-dependent recruitment of coactivator peptides to estrogen receptor using fluorescence polarization

Computational insights into the mechanism of ligand unbinding and selectivity of estrogen receptors.

Insights into ligand selectivity in estrogen receptor isoforms: molecular dynamics simulations and binding free energy calculations.

Multiple-targeting and Conformational Selection in the Estrogen Receptor: Computation and Experiment.

Prediction of binding affinity for estrogen receptor α modulators using statistical learning approaches

A Bipartite Recombinant Yeast System for the Identification of Subtype-Selective Estrogen Receptor Ligands

Asymmetric Allostery in Estrogen Receptor-α Homodimers Drives Responses to the Ensemble of Estrogens in the Hormonal Milieu

Identification of Estrogen Receptor α Antagonists from Natural Products via In Vitro and In Silico Approaches.

Novel Estrogen Receptor Ligands and Their Structure-Activity Relationship Evaluated by Scintillation Proximity Assay for High-Throughput Screening

Design, synthesis, biological evaluation and molecular docking studies of novel 3-aryl-4-anilino-2H-chromen-2-one derivatives targeting ERα as anti-breast cancer agents

Directed Evolution of Estrogen Receptor Proteins with Altered Ligand-Binding Specificities.

Cellular Reprogramming by the Conjoint Action of ERα, FOXA1, and GATA3 to a Ligand‐inducible Growth State

Discovery of novel natural compound inhibitors targeting estrogen receptor α by an integrated virtual screening strategy

LARMD: Integration of Bioinformatic Resources to Profile Ligand-Driven Protein Dynamics with a Case on the Activation of Estrogen Receptor.

Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in ESR1 mutant breast cancer cells

Integrative Model of Genomic Factors for Determining Binding Site Selection by Estrogen Receptor‐α